Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/8500

Target Organs and Levels of Evidence for TR-481

Toxicology and Carcinogenesis Studies of Oleic Acid Diethanolamine Condensate (CASRN 93-83-4) in F344/N Rats and B6C3F1 Mice (Dermal Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
Oleic acid diethanolamine condensate
93-83-4		 12/10/1997 Topical Application
R: 0, 50, OR 100 MG/KG; 50/SEX/GROUP M: 0, 15, OR 30 MG/KG; 55/SEX/GROUP		 Battelle Columbus Laboratory

Levels of Evidence

Male Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • SKIN: EPIDERMAL HYPERPLASIA; SEBACEOUS GLAND HYPERPLASIA; HYPERKERATOSIS; ACTIVE DERMAL INFLAMMATION
Female Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • SKIN: EPIDERMAL HYPERPLASIA; SEBACEOUS GLAND HYPERPLASIA; HYPERKERATOSIS; ACTIVE DERMAL INFLAMMATION
Male Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • SKIN: EPIDERMAL HYPERPLASIA; SEBACEOUS GLAND HYPERPLASIA; HYPERKERATOSIS; ACTIVE DERMAL INFLAMMATION
Female Mice: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • SKIN: EPIDERMAL HYPERPLASIA; SEBACEOUS GLAND HYPERPLASIA; HYPERKERATOSIS; ACTIVE DERMAL INFLAMMATION